Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B

Inclusion Criteria: * patients with Multiple sclerosis or neuromyelitis optica * diagnosed more than a year before inclusion * Expanded Disability Status Scale between 3.0 and 8.5 * all subtypes of multiple sclerosis or Neuromyelitis optica * Multiple Sclerosis patients who have previously been offered therapeutic alternatives available in indications and either decline or that after receiving treatment for at least 6 months have had an outbreak or an increase of at least 1 point on the Expanded Disability Status Scale (EDSS) (non-responders) or who have not tolerated treatment * Patients with Neuromyelitis optica (NMO) in stable immunomodulatory treatment in the past 6 months or without treatment because they are not candidates to receive it Exclusion Criteria: * Corticosteroid treatment in the last 30 days * Presence of an outbreak in the last month * Inability to perform brain Magnetic resonance imaging (with paramagnetic contrast) * Serious systemic diseases, including Hepatitis B virus, Hepatitis C Virus, and Human Immunodeficiency Virus. Uncontrolled hypertension, insulin-dependent diabetes mellitus, heart disease or kidney failure or severe respiratory * Personal history of cancer or family history of known hereditary cancer * patient participating in other experimental study in the last 3 months * women childbearing-aged that do not use effective contraceptive methods * pregnant or breastfeeding women